Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reduced prefrontal cortex response to own vs. unknown emotional infant faces in mothers with bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Modulatory Role of Serotonin on Human Impulsive Aggression

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Default mode network functional connectivity negatively associated with trait openness to experience

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Several electroencephalogram (EEG) biomarkers for prediction of drug response in major depressive disorder (MDD) have been proposed, but validations in larger independent datasets are missing. In the current study, we investigated the prognostic value of previously suggested EEG biomarkers. We gathered data that matched prior studies in terms of EEG methodology, clinical criteria for MDD, and statistical approach as closely as possible. The NeuroPharm study is a non-randomized and open label prospective clinical trial. One hundred antidepressant free patients with MDD were enrolled in the study and 79 (57 female) were included in the per-protocol analysis. The biomarkers candidates for cross-validation were derived from prior studies such as iSPOT-D and EMBARC and include frontal and occipital alpha power and asymmetry and delta and theta activity at anterior cingulate cortex (ACC). The alpha asymmetry, reported in two out of six prior studies, could be partially validated. We found that in female patients, larger right than left frontal alpha power prior to drug treatment was associated with better clinical outcome 8 weeks later. Moreover, female non-responder had higher central left alpha power relative to the right. In contrast to prior reports, we found that lower theta activity at ACC was present in remitters and was associated with greater improvement at week 8. We provide evidence that in women with MDD, alpha asymmetry seems to be the most promising EEG biomarker for prediction of treatment response. Registration number: NCT02869035.

OriginalsprogEngelsk
TidsskriftEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Vol/bind49
Sider (fra-til)101-112
Antal sider12
ISSN0924-977X
DOI
StatusUdgivet - aug. 2021

ID: 67559597